Company: INDP
Filing Date: 2025-03-27
Form Type: DRS
Source: 0001641172-25-000975
Chunk: 32

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-27
Form: DRS
Chunk 32
---
ION</div>

Pursuant to an engagement agreement dated , 2025 (the “engagement agreement”) we have engaged (the “Placement Agent”) to act as our exclusive placement agent to solicit offers to purchase the securities offered pursuant to this prospectus on a reasonable best efforts basis. The engagement agreement does not give rise to any commitment by the Placement Agent to purchase any of our securities, and the Placement Agent will have no authority to bind us by virtue of the engagement agreement. The Placement Agent is not purchasing or selling any of the securities offered by us under this prospectus, nor is it required to arrange for the purchase or sale of any specific number or dollar amount of securities, other than to use its “reasonable best efforts” to arrange for the sale of such securities by us. Therefore, we may not sell all of the securities being offered. The terms of this offering were subject to market conditions and negotiations between us, the Placement Agent and prospective investors. This is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering. Because there is no minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us. The Placement Agent does not guarantee that it will be able to raise new capital in any prospective offering. The Placement Agent may engage sub-agents or selected dealers to assist with the offering.

Investors purchasing securities offered hereby will have the option to execute a securities purchase agreement with us. In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers which enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract is material to larger purchasers in this offering as a means to enforce (i) a covenant to not enter into variable rate financings for a period of following the closing of the offering, subject to certain conditions and exceptions, and (ii) a covenant to not enter into any equity financings for from closing of the offering, subject to certain exceptions. The nature of the representations, warranties and covenants in the securities purchase agreements shall include:

| ● | standard                                                                                             
 issuer representations and warranties on matters such as organization, qualification, authorization, 
 no conflict, no governmental filings required, current in SEC filings, no litigation, labor          
 or other compliance issues, environmental, intellectual property and title matters and compliance    
 with